FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Eight studies of a total two hundred twenty-one identified met strict inclusion criteria and were included in the meta-analysis. The hazard ratio of cognitive decline for case-controlled studies (n=6) was 1.37 (95% CI 1.06-1.77, p = 0.02). For controlled studies (n=2) the hazard ratio of cognitive decline was 1.57 (95% CI 0.50-4.92, p = 0.44).
The authors concluded that the impact of ADT on cognitive decline was unclear based on controlled intervention studies. However, in case-controlled studies, there appeared to be a negative impact of ADT on cognitive functioning. The authors cautioned not to over-interpret these data in light of their retrospective nature and risk of bias. Future prospective studies are needed to better understand the relationship between ADT and long term risk of dementia.
First Author: Maxine Sun, Brigham and Women’s Hospital, Harvard Medical School
Written By: Benjamin T. Ristau, M.D., Fox Chase Cancer Center
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA